Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical evidence from the KEYNOTE-716 trial demonstrates a clear clinical advantage for pembrolizumab, showing significant improvement in recurrence-free survival and distant metastasis-free survival compared to placebo. However, overall survival data remains immature, which prevents a higher rating.
Cost effectiveness
The cost-effectiveness estimates for pembrolizumab are likely within NICE’s acceptable range, with ICERs around £20,000 per QALY gained. Despite some uncertainties in the economic model, the overall assessment supports its cost-effectiveness.
Quality of life
While the document does not provide extensive HRQoL data, the evidence suggests that pembrolizumab may improve quality of life by reducing the fear of recurrence in patients with resected melanoma. However, the potential for severe adverse effects may offset some of these benefits.
Supporting Domains
Safety and Adverse Effects
Pembrolizumab has a very good safety profile, with manageable adverse events. The committee noted that while about 10% of patients may experience permanent adverse effects, the overall tolerability is considered acceptable.
Comparator Selection
The treatment was compared against placebo in a well-designed Phase 3 trial, which is appropriate for assessing its efficacy. The use of placebo as a comparator is justified given the lack of available adjuvant treatments for this patient population.
Patient Population and Subgroups
The KEYNOTE-716 trial population is considered representative of the Healthcare patient population, with adequate subgroup analyses. However, the trial’s demographic skew towards white participants may limit generalizability to other ethnic groups.
Care Pathway Integration
Pembrolizumab can be integrated into existing treatment pathways with minor adjustments, as clinicians are already familiar with its use in later-stage melanoma treatments. This facilitates its adoption in clinical practice.
Resource Use and Cost Implications
The resource implications of pembrolizumab are manageable, with the potential for cost savings through reduced recurrence rates. The economic model indicates that the treatment is likely to be resource-efficient.
Evidence Quality and Robustness
The evidence base is supported by a robust Phase 3 trial with low bias risk. However, the immaturity of overall survival data introduces some uncertainty, preventing a higher rating.
Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding overall survival and subsequent treatment pathways, the context of unmet need and the potential benefits of pembrolizumab mitigate some of these concerns.
